Expression of an immunologically reactive merozoite surface protein (MSP-1(42)) in E. coli

Area of Science:

• Malariology
• Vaccine Development
• Protein Expression Systems

Background:

• Plasmodium falciparum merozoite surface protein-1 (PfMSP-1(42)) is a critical antigen for malaria vaccine development.
• Existing recombinant protein expression systems face challenges in yield and cost-effectiveness.

Purpose of the Study:

• To develop and evaluate a novel E. coli expression system for producing recombinant PfMSP-1(42).
• To assess the antigenicity and immunogenicity of the bacterially expressed PfMSP-1(42) compared to a baculovirus-expressed counterpart.

Main Methods:

• Recombinant PfMSP-1(42) was expressed as a fusion protein in a novel E. coli host.
• Purified protein yield was determined (average 48 mg/l).
• Antigenicity and immunogenicity were assessed via T and B cell responses, in vitro parasite inhibition, and monoclonal antibody cross-reactivity.

Main Results:

• The E. coli system achieved a high yield of recombinant PfMSP-1(42).
• The bacterially expressed protein exhibited significant similarities to the baculovirus-expressed version (Bmp42).
• Immunological evaluations showed comparable immunoreactivity between the two recombinant proteins.

Conclusions:

• The novel E. coli expression system is effective for producing immunologically active recombinant PfMSP-1(42) at high levels.
• This bacterial system offers a potentially cost-effective alternative for producing malaria vaccines for human use.